Observational studyPloS one2026
Retinal macrophage-like cell activation and ganglion cell layer thinning are associated with disability and MRI lesion burden in multiple sclerosis.
Observational study in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple sclerosis is a chronic neuroinflammatory disease in which microglia and macrophage-like cells play a central role in disease progression. The retina, as a central nervous system extension accessible to non-invasive imaging, offers a unique window into these processes.
objectiveThe aim of this study was to determine whether retinal macrophage-like cell characteristics and ganglion cell layer thickness are associated with clinical disability and magnetic resonance imaging lesion burden in patients with multiple sclerosis.
methodsIn this cross-sectional observational study, patients with multiple sclerosis and age-matched healthy controls underwent retinal imaging using spectral-domain optical coherence tomography and swept-source optical coherence tomography angiography. Macrophage-like cells at the vitreoretinal interface were quantified using an automated image-processing pipeline, while ganglion cell layer and retinal nerve fibre layer thicknesses were measured using standardized segmentation. Clinical disability was assessed using the Expanded Disability Status Scale, the 9-Hole Peg Test, and the 25-Foot Walk. Brain magnetic resonance imaging lesion counts were obtained from T1- and T2-weighted sequences.
resultsOverall retinal macrophage-like cell parameters did not differ between patients with multiple sclerosis and controls. However, patients with greater disability, defined as an Expanded Disability Status Scale score of five or higher, showed significantly increased macrophage-like cell count and density. Macrophage-like cell size demonstrated a moderate positive association with T2 lesion burden, while only weak associations were observed with T1 lesions. Ganglion cell layer thickness was significantly reduced in the inferior and nasal macular regions in patients with multiple sclerosis compared with controls, whereas retinal nerve fibre layer thickness was preserved. Disability scores showed moderate correlations with upper and lower limb functional tests.
conclusionsThese findings indicate that retinal cellular and structural alterations reflect both inflammatory and neurodegenerative components of multiple sclerosis. Retinal macrophage-like cell metrics are associated with disease burden and disability, while ganglion cell layer thinning provides evidence of neuroaxonal loss. Retinal imaging may serve as a non-invasive complement to magnetic resonance imaging for assessing disease severity and progression in multiple sclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.